Linagliptin Stada

Linagliptin, the active ingredient in Linagliptin Stada, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus when combined with diet and exercise.

GNH USA supplies Linagliptin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor indicated for the management of type 2 diabetes mellitus. It helps achieve better glycaemic control when used as part of a comprehensive treatment plan.

- Type 2 diabetes mellitus: improves glycaemic control in adults when combined with diet and exercise.

Common side effects are generally mild and may resolve without intervention.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient head discomfort. - Dizziness: occasional light‑headed sensation. - Gastrointestinal upset: includes nausea or abdominal discomfort. - Upper respiratory tract infection: mild cold‑like symptoms. - Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: such as angioedema or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes. - Bullous pemphigoid: rare skin blistering disorder. - Stevens‑Johnson syndrome: serious skin reaction.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential adverse events.

- Renal impairment: assess kidney function and adjust therapy as needed. - Hepatic impairment: monitor liver enzymes regularly. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Elderly patients: watch for hypoglycaemia when used with other glucose‑lowering agents. - Concomitant sulfonylureas or insulin: increased risk of hypoglycaemia; monitor glucose levels. - Store at room temperature: keep in the original container, protect from moisture and heat.

Linagliptin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Insulin or sulfonylureas: may cause severe hypoglycaemia. - Strong P‑gp inhibitors (e.g., itraconazole): can increase linagliptin exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma levels.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce linagliptin effectiveness. - Diuretics: monitor renal function and electrolytes. - ACE inhibitors: watch blood pressure and renal parameters.